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Abstract
Objective To examine compliance with mandatory reporting of summary
clinical trial results (within one year of completion of trial) on
ClinicalTrials.gov for studies that fall under the recent Food and Drug
Administration Amendments Act (FDAAA) legislation.
Design Registry based study of clinical trial summaries.
Data sources ClinicalTrials.gov, searched on 19 January 2011, with
cross referencing with Drugs@FDA to determine for which trials
mandatory reporting was required within one year.
Selection criteria Studies registered on ClinicalTrials.gov with US sites
which completed between 1 January and 31 December 2009.
Main outcome measure Proportion of trials for which results had been
reported.
Results The ClinicalTrials.gov registry contained 83 579 entries for
interventional trials, of which 5642 were completed within the timescale
of interest. We identified trials as falling within the mandatory reporting
rules if they were covered by the FDAAA (trials of a drug, device, or
biological agent, which have at least one US site, and are of phase II or
later) and if they investigated a drug that already had approval from the
Food and Drug Administration. Of these, 163/738 (22%) had reported
results within one year of completion of the trial compared with 76/727
(10%) trials that were not subject to mandatory reporting (95% confidence
interval for the difference in proportions 7.8% to 15.5%; χ2 test,
P=2.6×10−9). Later phase trials were more likely to report results
(P=4.4×10−11), as were industry funded trials (P=2.2×10−16).
Conclusion Most trials subject to mandatory reporting did not report
results within a year of completion.
Introduction
A key principle in the good conduct of clinical trials is that a
summary of the trial protocol should be freely available while
the study is ongoing and that, on completion of the study, the
results should be readily accessible to all in a timely fashion.
In February 2000 the Food and Drug Administration (FDA)
Modernization Act (1997) prompted the creation of a national
clinical trials registry (ClinicalTrials.gov).1 2 Similar databases
(such as the ISRCTN) have been established elsewhere. From
2005 the International Committee of Medical Journal Editors
(ICMJE) required that clinical trials should be indexed in a
clinical trial registry to qualify for publication in a journal
following the uniform requirements for manuscripts.3
Subsequently, the FDA Amendments Act (FDAAA) of 2007
required registration of summaries of trial protocols for
“applicable clinical trials” (trials that are covered by the
FDAAA).4 These are trials that have at least one site in the
United States; are of a drug, device, or biological agent; and are
“initiated or ongoing as of September 2007,” excluding phase
I studies and early feasibility trials of devices.5 Clinical trials
are registered with ClinicalTrials.gov (clinicaltrials.gov) by
“responsible parties” and uploaded to the website by using the
Protocol Registration System (http://prsinfo.clinicaltrials.gov).
The uploading of trial results is achieved in a similar fashion
and reviewed by a Protocol Registration System administrator
before publication on ClinicalTrials.gov. At present, clinical
trials of drugs that already have FDA approval are required to
report results within one year of completion of the trial (with
some provisions for delayed reporting), although in the future
applicable clinical trials of unapproved drugs or biological
agents that are regulated by the FDA may also be required to
report results.6 These results are posted in the form of a table of
values for each of the pre-specified primary and secondary
outcome measures for each arm of the clinical trial, with
associated statistical tests.
This new legislation should help to overcome the problem of
trials that are done but not reported.7 Zarin et al have recently
described the current activity of ClinicalTrials.gov,8 and Wood
has given a thoughtful discussion of the current legislation,6 but
no systematic evaluation of compliance with the FDAAA has
been published (to the best of our knowledge). Zarin et al
recently commented that the “usefulness [of ClinicalTrials.gov]
depends upon the research community to submit accurate,
informative data.” While searching the ClinicalTrials.gov
database, we noted that studies under the jurisdiction of the
FDAAA had not yet reported basic results. We decided to look
into this further.
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Studies of a drug, device, or biological agent with a site in the
United States that completed in 2009 are subject to the FDAAA
regulations and are required to submit a protocol summary to
ClinicalTrials.gov. Of these, most trials of drugs approved by
the FDA are subject to mandatory reporting within a year. Our
aimwas to systematically assess the compliance with mandatory
reporting on ClinicalTrials.gov of interventional clinical trials
falling under the FDAAA and to look for evidence of reporting
bias by using publicly available datasets.
We did a database search of trials registered on
ClinicalTrials.gov which completed in 2009 and are covered
by the FDAAA. To identify the subgroup of these studies for
which mandatory reporting is required within one year of study
completion, we cross referenced our search results with
Drugs@FDA (the US database of FDA approved drugs).
Methods
Not all trials registered with ClinicalTrials.gov are covered by
the FDAAA, and only a proportion of those covered by the
FDAAA are required to report results within one year (“trials
subject to mandatory reporting”). We identified this group of
trials as follows. We searched ClinicalTrials.gov (search date
19 January 2011) for all intervention studies. We identified
completed studies by using the “primary completion date” field
(or, where this was not recorded, the “completion date”). The
primary completion date, as defined by ClinicalTrials.gov, is
the date of collection of primary outcome data on the last patient
to be enrolled. The completion date is the date of completion
of the study, as defined by the individual trial’s investigators.
We selected trials subject to mandatory reporting (within one
year) which were completed between 1 January and 31
December 2009. We chose these dates because all the studies
completing within this timeframe would have had at least one
year in which to report results.
We excluded phase 0 and I trials, as well as trials that did not
report a phase. We used a script to programmatically obtain the
study site(s) for each trial. We excluded studies that did not
have a site in the United States. Additionally, we excluded
studies that were not clinical trials of a drug, biological therapy,
or device. The remaining studies therefore consisted of trials
that are covered by the FDAAA.
Trials of drugs that are not approved by the FDA at the time of
the 12 month deadline are not yet required to be reported. We
cross referenced the investigational drug for each of the
applicable clinical trials with the FDA database of approved
drugs, Drugs@FDA (www.accessdata.fda.gov/scripts/cder/
drugsatfda/index.cfm), to identify trials of approved drugs
(hereafter termed “trials subject to mandatory reporting”—see
data supplement (http://dx.doi.org/10.5061/dryad.j512f21p) for
further description and examples of this classification). Owing
to the nature of the records available on Drugs@FDA, this
removed devices and some biological agents from themandatory
reporting dataset. For the primary analysis, we categorised a
drug as being FDA approved if the active compound listed on
ClinicalTrials.gov was listed as an approved drug on
Drugs@FDA. For example, if tobramycin was administered by
injection in the trial, we classified this as an approved drug, as
tobramycin products administered by injection are approved on
Drugs@FDA. However, for a trial in which tobramycin was
administered as a dry powder for inhalation, we did not classify
this as an approved drug, as this formulation was not approved
on Drugs@FDA at the time of our search. One investigator
(APP) classified all drugs. Another investigator (MNH)
classified a 10% sample of these to measure inter-rater
agreement.
We occasionally had difficulty in deciding whether a generic
drug listed in a ClinicalTrials.gov record was in fact a
formulation approved by the FDA. For this reason, we did a
subgroup analysis in which only drugs approved by the FDA
and identified by brand name on ClinicalTrials.gov were
considered approved drugs.
We compared the reporting rate of trials subject to mandatory
reporting with trials that fall under the FDAAA but are not
subject to mandatory reporting. We examined the relation of
phase of study and funder of the trial with reporting of results
for trials subject to mandatory reporting.
We imported the dataset from ClinicalTrials.gov intoMicrosoft
Excel. We used R (R-Foundation for Statistical Computing,
Vienna, Austria; version 2.12.1) to “webscrape” additional
information from the ClinicalTrials.gov website.9 We analysed
the final reported dataset by using R. Further details of the
categorisation of trials, the complete dataset, and R scripts to
produce the results that we report here are available as data
supplements (http://dx.doi.org/10.5061/dryad.j512f21p).
Results
At the time of our search, the ClinicalTrials.gov registry
included 83 579 entries for intervention studies (figure⇓). Of
these, we identified 31 556 as having “completed,” and 5642
had completion dates between 1 January and 31December 2009.
We excluded phase 0 and I studies (n=1098), as well as trials
that did not indicate a phase of clinical study (1170), those that
did not have a US site (1752), and trials that were not of a
device, drug, or biological agent (157). This established a group
of 1465 trials covered by the FDAAA, for which more than a
year had passed since completion in which to report results.
Reporting for applicable trials is (at present) mandatory only
for drugs, biological agents, or devices approved by the FDA.
By cross referencing with Drugs@FDA (www.accessdata.fda.
gov/scripts/cder/drugsatfda/index.cfm), we found that 738 trials
covered by the FDAAA were subject to mandatory reporting.
APP categorised drugs from trials as previously approved by
the FDA. MNH repeated this classification for a sample of 150
(10%) of the records. Disagreement resolved by discussion led
to a change in classification in 3/150 (2%) of records.
Of the 738 trials that were classified as subject to mandatory
reporting, 163 (22%) had reported results. In comparison, 76/727
(10%) trials covered by the FDAAA but not subject to
mandatory reporting had reported results (95% confidence
interval for the difference in proportions 7.8% to 15.5%; χ2 test,
P=2.6×10−9).
The proportion of trials subject to mandatory reporting that had
reported results was influenced by the phase of the study (table
1⇓). Fewer phase II trials had reported results compared with
phase III and IV trials (χ2 test, P=4.4×10−11). We categorised
the funder of the trial as industry, mixed, National Institutes of
Health/government, or other and found that the funder of the
trial influenced the proportion that had reported results (Fisher’s
exact test, P=2.2×10−16) (table 2⇓). Industry funded trials were
more likely to report results. We therefore grouped trials subject
to mandatory reporting into “solely industry funded” and “not
solely industry funded.” More solely industry funded studies
(126/317; 40%) had reported results than had those not solely
industry funded (37/421 (9%); 95% confidence interval for the
difference 24.7% to 37.3%; χ2 test, P=2.2×10−16).
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We did a subgroup analysis to determine the proportion of trials
that gave the brand name of the investigated drug on the
ClinicalTrials.gov record (for which we had more confidence
in our categorisation of the drug as being approved by the FDA)
which reported results. Of the 738 drug trials that we had
classified as being subject to mandatory reporting, 347 trials
gave the brand name for each and every drug in the trial. Of
these 347 trials, 96 (28%) had reported results.
Discussion
Reporting of summary results on ClinicalTrials.gov is an
important step forward in reducing bias in the literature. We
have cross referenced the ClinicalTrials.gov and Drugs@FDA
databases to produce a dataset of trials that should have reported
results at the time of our search, and we found that only 22%
of trials had done so. If the reporting rate does not increase, the
laudable FDAAA legislation will not achieve its goal of
improving the accessibility of trial results.
The influence of funding body and sponsor seems to be
considerable. Industry funded trials subject to mandatory
reporting were more likely to report results compared with other
funders. Phase III and IV studies seemmore likely to be reported
than phase II studies.
Comparison with literature
Many potential sources of bias may skew the literature.10 11Apart
from citation bias, these biases can be ascribed to the
investigator, sponsor, and publisher. Although studies with
positive results are published more quickly,12-14 no significant
relation seems to exist between trial results and time between
submission of a manuscript to a journal and publication.15
ClinicalTrials.gov allows dissemination of summary results
independent of a publisher. Our study supports the suggestion
that study investigators and sponsors act as the principal sources
of reporting bias; reporting of results to ClinicalTrials.gov is
independent of peer review, manuscript preparation, and
editorial priorities.
Strengths and limitations of study
The FDAAA requirements for mandatory reporting came into
force during 2008. By selecting studies that completed during
2009, and doing our search in early 2011, we have ensured that
the trials completed during the period when the FDAAA was
applicable and that at least one year had elapsed for data to be
submitted to ClinicalTrials.gov. We are reliant on responsible
parties from each study uploading accurate data to
ClinicalTrials.gov. We believe that our search in January 2011
represents the earliest reasonable time to do our study. We
anticipate (and hope) that as more investigators become familiar
with the legislation, reporting rates will increase. As we present
a cross sectional study from a single year, we cannot comment
on trends in reporting of results.
An important limitation of the study is that we have identified
trials subject to mandatory reporting through publicly available
summary data on the trials. We categorised a trial as covered
by the FDAAA if it had at least one site in the United States,
was Phase II or later, and investigated a device, drug, or
biological agent. The possibility remains of misclassification
of trials as either FDAAA applicable or FDAAAnon-applicable,
owing to the nature of the information available to us on
ClinicalTrials.gov.
We identified a group of trials subject to mandatory reporting
by cross referencing the ClinicalTrials.gov record with
Drugs@FDA (the online database of FDA approved drugs).
This was straightforward when the brand name of the drug was
listed in the ClinicalTrials.gov record and that product had FDA
approval. Similarly, categorising drugs as non-FDA approved
when the brand name drug was not listed on Drugs@FDA or
when a generic form with a different formulation or route of
administration to the FDA approved product was used in the
trial was a simple process. We had more difficulty in
categorising a drug administered in a trial if the generic name
given in the ClinicalTrials.gov record was approved by the FDA,
as the approved drug may not necessarily have been the
formulation administered in the trial. In these cases, we took an
inclusive approach and included these trials in our mandatory
reporting required group. We did a subgroup analysis using
only trials of drugs for which the brand name of the drug was
given in the trial (thus eliminating uncertainty as to whether the
formulation in the trial was or was not FDA approved). In this
analysis, 28% of trials had reported results, broadly similar to
the 22% that we found with the more inclusive approach.
We have no data on the number of studies that applied for
exemptions from the requirement for reporting. Industry funded
studies are perhaps most likely to form part of an application
for licensing/marketing, and therefore most likely to apply for
an exemption, but we have found that industry funded studies
are more likely to report results than are studies funded by other
means. We also note that trials investigating new indications
for drugs previously approved by the FDA are not required to
upload results until two years after completion, but our methods
did not allow us to identify these trials.
Although these various effects could increase our denominator
and falsely decrease the overall reporting effect, we believe that
this is unlikely to account for approximately 78% of the trials
not reporting. Phase IV trials are (by definition) trials of drugs
that have marketing approval, and so are of an FDA approved
drug, and the indication studied in the trial should be the same
as the approved indication. All of these studies should have
reported results within one year, and yet only 31.3% had done
so (table 1⇓). Although our denominator is necessarily somewhat
uncertain, owing to the nature of the data that are publicly
available, we believe that many clinical trials that should have
reported basic results had not.
Conclusions and policy implications
Through studying the ClinicalTrials.gov database, which
mandates the reporting of outcomes of completed but
unpublished studies, we believe that an understanding of the
extent of bias in the literature due to unpublished studies can
be gained. This will be of great benefit to the clinicians who
prescribe new treatments, the patients who take them, healthcare
funders, and especially researchers doing systematic reviews
of treatment interventions which inform all of the above. The
availability of both the protocol and results in outline form helps
to overcome both outcome reporting bias and publication bias.
We report a systematic approach to examining compliance with
mandatory reporting. In a study such as ours, which uses only
publicly available data and cross references one dataset to
another, some debate will inevitably take place about whether
we have accurately identified trials that fall under the FDAAA
requirement for mandatory reporting. Within the limitations of
our study design, we have identified a group of trials of which
the vast majority should have reported summary results within
a year and had not done so.
We believe that the FDAAA is an important milestone on the
path to a future in which all the available evidence can be used
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to make decisions about treatment, andwe applaud the farsighted
nature of the legislation. We have found that trials subject to
mandatory reporting are more likely to have reported results
compared with other trials, illustrating the positive effect of the
legislation and efforts of ClinicalTrials.gov. Nevertheless,
overall reporting is poor.
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What is already known on this topic
Reporting bias prevents the dissemination of results of clinical trials
Where trial data are not accessible to practitioners, clinical decisions cannot be based on the best evidence and may be flawed
Recent US legislation mandates publication of a results summary on ClincalTrials.gov for recent trials of drugs approved by the Food
and Drug Administration and should improve access to trial results
What this study adds
At the time of the search, many trials that should have published data on ClincalTrials.gov had not done so
Tables
Table 1| Number of trials subject to mandatory reporting which had reported results, grouped by phase of study
PercentageTotalNo with resultsPhase
1032934II
3222973III
3118056IV
22738163Total
χ2 test for effect of study phase (II, III, or IV) influencing proportion of trials with results: P=4.4×10−11.
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Table 2| Number of trials subject to mandatory reporting which had reported results, grouped by funder of study
PercentageTotalNo with resultsFunder
40317126Industry
926525Mixed
8484NIH/government
71088Other
22738163Total
NIH=National Institutes of Health.
Fisher’s exact test for effect of funder influencing proportion of trials with results: P=2.2×10−16.
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Figure
Flow diagram to show selection of trials
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